Aerie Pharmaceuticals, Inc.
COMBINATION THERAPY

Last updated:

Abstract:

Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Status:
Application
Type:

Utility

Filling date:

7 Dec 2021

Issue date:

24 Mar 2022